Envision Pharma Group Limited secures £614k in latest funding round

Improving patient outcomes through the distribution of eye health supplements across African markets is the core mission of Envision Pharma Group Limited, which has just raised an estimated £614k. Based in Horsham, the company operates as a technology-enabled solutions partner for the life sciences industry. It provides a range of services including medical affairs, healthcare communications software, and strategic consulting for pharmaceutical, biotechnology, and medical device companies.

The company was incorporated in 2016 and focuses on the localization of clinically proven eye care innovations. Its service suite covers commercialization, market access, revenue management, and compliance solutions. Envision Pharma Group Limited supports healthcare professionals by managing regulatory expertise and maintaining a supply chain for science-led treatments. The business aims to make world-class eye care accessible across Africa by bridging the gap between global innovations and local markets.

This latest funding (allotted in April 2026) follows a series of previous capital raises over the last decade. The company secured £2.2m in July 2024 and £10.6m in February 2023. Prior to these rounds, it raised £48.9m in September 2017 and £1.3m in July 2016.

Financial records for the year ended 31 December 2024 show the company reported a £186.3m loss. Current LinkedIn data indicates the organization has 0 employees, though it maintains an active digital presence through a dedicated website focused on its South African operations. The company provides science-led products and regulatory expertise to support the healthcare infrastructure in the regions it serves.